Minireview: The Link Between ERα Corepressors and Histone Deacetylases in Tamoxifen Resistance in Breast Cancer
Open accessThe DOI matches its Crossref record; 121 of the 121 references it cites were found in a registry or an index.
Abstract
Approximately 70% of breast cancers express the estrogen receptor (ER)α and are treated with the ERα antagonist, tamoxifen. However, resistance to tamoxifen frequently develops in advanced breast cancer, in part due to a down-regulation of ERα corepressors. Nuclear receptor corepressors function by attenuating hormone responses and have been shown to potentiate tamoxifen action in various biological systems. Recent genomic data on breast cancers has revealed that genetic and/or genomic events target ERα corepressors in the majority of breast tumors, suggesting that the loss of nuclear receptor corepressor activity may represent an important mechanism that contributes to intrinsic and acquired tamoxifen resistance. Here, the biological functions of ERα corepressors are critically reviewed to elucidate their role in modifying endocrine sensitivity in breast cancer. We highlight a mechanism of gene repression common to corepressors previously shown to enhance the antitumorigenic effects of tamoxifen, which involves the recruitment of histone deacetylases (HDACs) to DNA. As an indicator of epigenetic disequilibrium, the loss of ERα corepressors may predispose cancer cells to the cytotoxic effects of HDAC inhibitors, a class of drug that has been shown to effectively reverse tamoxifen resistance in numerous studies. HDAC inhibition thus appears as a promising therapeutic approach that deserves to be further explored as an avenue to restore drug sensitivity in corepressor-deficient and tamoxifen-resistant breast cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Elkablawy, M. A., Albasri, A. M., Mohammed, R. A., Hussainy, A. S., Nouh, M. M., & Alhujaily, A. S. (2016) · Saudi Medical Journal · doi:10.15537/smj.2016.2.12285 · Cited by 4,382
Györffy, B., Lanczky, A., Eklund, A. C., Denkert, C., Budczies, J., Li, Q., & Szallasi, Z. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0674-9 · Cited by 4,169
Shiau, A. K., Barstad, D., Loria, P. M., Cheng, L., Kushner, P. J., Agard, D. A., & Greene, G. L. (1998) · Cell · doi:10.1016/s0092-8674(00)81717-1 · Cited by 2,729
COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
Forbes, S. A., Bindal, N., Bamford, S., Cole, C., Kok, C. Y., Beare, D., Jia, M., Shepherd, R., Leung, K., Menzies, A., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq929 · Cited by 2,278
Global estimates of cancer prevalence for 27 sites in the adult population in 2008
Bray, F., Ren, J., Masuyer, E., & Ferlay, J. (2013) · International Journal of Cancer · doi:10.1002/ijc.27711 · Cited by 1,891
Cofactor Dynamics and Sufficiency in Estrogen Receptor–Regulated Transcription
Shang, Y., Hu, X., DiRenzo, J., Lazar, M. A., & Brown, M. (2000) · Cell · doi:10.1016/s0092-8674(00)00188-4 · Cited by 1,657
Métivier, R., Penot, G., Hübner, M. R., Reid, G., Brand, H., Koš, M., & Gannon, F. (2003) · Cell · doi:10.1016/s0092-8674(03)00934-6 · Cited by 1,431
Genome-wide analysis of estrogen receptor binding sites
Carroll, J. S., Meyer, C. A., Song, J., Li, W., Geistlinger, T. R., Eeckhoute, J., Brodsky, A. S., Keeton, E. K., Fertuck, K. C., Hall, G. F., et al. (2006) · Nature Genetics · doi:10.1038/ng1901 · Cited by 1,377
Estrogen Actions in the Central Nervous System1
McEwen, B. S., & Alves, S. E. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.3.0365 · Cited by 1,358
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
Toy, W., Shen, Y., Won, H., Green, B., Sakr, R. A., Will, M., Li, Z., Gala, K., Fanning, S., King, T. A., et al. (2013) · Nature Genetics · doi:10.1038/ng.2822 · Cited by 1,248
A complex containing N-CoR, mSln3 and histone deacetylase mediates transcriptional repression
Heinzel, T., Lavinsky, R. M., Mullen, T.-M., Söderström, M., Laherty, C. D., Torchia, J., Yang, W.-M., Brard, G., Ngo, S. D., Davie, J. R., et al. (1997) · Nature · doi:10.1038/387043a0 · Cited by 1,214
(2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70425-4 · Cited by 1,160
Shou, J., Massarweh, S., Osborne, C. K., Wakeling, A. E., Ali, S., Weiss, H., & Schiff, R. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh166 · Cited by 1,153
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
Robinson, D. R., Wu, Y.-M., Vats, P., Su, F., Lonigro, R. J., Cao, X., Kalyana-Sundaram, S., Wang, R., Ning, Y., Hodges, L., et al. (2013) · Nature Genetics · doi:10.1038/ng.2823 · Cited by 1,145
Phosphatidylinositol 3-Kinase/AKT-mediated Activation of Estrogen Receptor α
Campbell, R. A., Bhat-Nakshatri, P., Patel, N. M., Constantinidou, D., Ali, S., & Nakshatri, H. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010840200 · Cited by 968
Overview of the main outcomes in breast-cancer prevention trials
Cuzick, J., Powles, T., Veronesi, U., Forbes, J., Edwards, R., Ashley, S., & Boyle, P. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12342-2 · Cited by 965
Tamoxifen: a most unlikely pioneering medicine
Jordan, V. C. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1031 · Cited by 824
Nuclear factor RIP140 modulates transcriptional activation by the estrogen receptor.
Cavaillès, V., Dauvois, S., L'Horset, F., Lopez, G., Hoare, S., Kushner, P. J., & Parker, M. G. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb00044.x · Cited by 751
Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes.
Lavinsky, R. M., Jepsen, K., Heinzel, T., Torchia, J., Mullen, T.-M., Schiff, R., Del-Rio, A. L., Ricote, M., Ngo, S., Gemsch, J., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.6.2920 · Cited by 660
Mechanisms of tamoxifen resistance
Ring, A., & Dowsett, M. (2004) · Endocrine-Related Cancer · doi:10.1677/erc.1.00776 · Cited by 651
Chen, H., Lin, R. J., Xie, W., Wilpitz, D., & Evans, R. M. (1999) · Cell · doi:10.1016/s0092-8674(00)80054-9 · Cited by 637
Both corepressor proteins SMRT and N‐CoR exist in large protein complexes containing HDAC3
Li, J., Wang, J., Wang, J., Nawaz, Z., Liu, J. M., Qin, J., & Wong, J. (2000) · The EMBO Journal · doi:10.1093/emboj/19.16.4342 · Cited by 629
The SMRT and N-CoR Corepressors Are Activating Cofactors for Histone Deacetylase 3
Guenther, M. G., Barak, O., & Lazar, M. A. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.18.6091-6101.2001 · Cited by 611
Osborne, C. K., Shou, J., Massarweh, S., & Schiff, R. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.865s.11.2 · Cited by 462
Kao, H.-Y., Downes, M., Ordentlich, P., & Evans, R. M. (2000) · Genes & Development · doi:10.1101/gad.14.1.55 · Cited by 424
Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice.
Osborne, C. K., Hobbs, K., & Clark, G. M. (1985) · PubMed · Cited by 402
Munster, P. N., Thurn, K. T., Thomas, S., Raha, P., Lacevic, M., Miller, A., Melisko, M., Ismail-Khan, R., Rugo, H., Moasser, M., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.156 · Cited by 391
Estrogen actions in the central nervous system
McMillan, P. J., & Dorsa, D. M. (1999) · Current Opinion in Endocrinology & Diabetes · doi:10.1097/00060793-199902000-00006 · Cited by 390
Bertolotti, A., Lutz, Y., Heard, D. J., Chambon, P., & Tora, L. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00882.x · Cited by 365
Altucci, L., Addeo, R., Cicatiello, L., Dauvois, S., Parker, M., Truss, M., Beato, M., Sica, V., Bresciani, F., & Weisz, A. (1996) · PubMed · Cited by 343
Zhang, Q., Borg, Å., Wolf, D. M., Oesterreich, S., & Fuqua, S. A. W. (1997) · PubMed · Cited by 337
Hormone receptors: their role in predicting prognosis and response to endocrine therapy.
McGuire, W. L. (1978) · PubMed · Cited by 335
Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells
Doisneau-Sixou, S. F., Sergio, C. M., Carroll, J. S., Hui, R., Musgrove, E. A., & Sutherland, R. L. (2003) · Endocrine Related Cancer · doi:10.1677/erc.0.0100179 · Cited by 333
Sharp, an inducible cofactor that integrates nuclear receptor repression and activation
Shi, Y., Downes, M., Xie, W., Kao, H.-Y., Ordentlich, P., Tsai, C.-C., Hon, M., & Evans, R. M. (2001) · Genes & Development · doi:10.1101/gad.871201 · Cited by 329
Huang, E. Y., Zhang, J., Miska, E. A., Guenther, M. G., Kouzarides, T., & Lazar, M. A. (2000) · Genes & Development · doi:10.1101/gad.14.1.45 · Cited by 325
Early Menarche, a Risk Factor for Breast Cancer, Indicates Early Onset of Ovulatory Cycles*
APTER, D., & VIHKO, R. (1983) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-57-1-82 · Cited by 323
Montano, M. M., Ekena, K., Delage-Mourroux, R., Chang, W., Martini, P., & Katzenellenbogen, B. S. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.12.6947 · Cited by 296
Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents
Licciardi, P., Ververis, Hiong, & Karagiannis (2013) · Biologics: Targets and Therapy · doi:10.2147/btt.s29965 · Cited by 274
Bertolotti, A., Melot, T., Acker, J., Vigneron, M., Delattre, O., & Tora, L. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.3.1489 · Cited by 261
Progesterone signalling in breast cancer: a neglected hormone coming into the limelight
Brisken, C. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3518 · Cited by 255
Coexpression of estrogen receptor alpha and beta: poor prognostic factors in human breast cancer?
Speirs, V., Parkes, A., Kerin, M. J., Walton, D. S., Carleton, P. J., Fox, J. N., & Atkin, S. L. (1999) · PubMed · Cited by 255
García-Becerra, R., Santos, N., Díaz, L., & Camacho, J. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms14010108 · Cited by 253
Girault, I., Lerebours, F., Amarir, S., Tozlu, S., Tubiana-Hulin, M., Lidereau, R., & Bièche, I. (2003) · PubMed · Cited by 193
The biology of progesterone receptor in the normal mammary gland and in breast cancer
Obr, A. E., & Edwards, D. P. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.10.030 · Cited by 189
A SANT motif in the SMRT corepressor interprets the histone code and promotes histone deacetylation
Yu, J. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg326 · Cited by 180
Grober, O. M., Mutarelli, M., Giurato, G., Ravo, M., Cicatiello, L., De Filippo, M. R., Ferraro, L., Nassa, G., Papa, M. F., Paris, O., et al. (2011) · BMC Genomics · doi:10.1186/1471-2164-12-36 · Cited by 173
Shibata, H. (1997) · Molecular Endocrinology · doi:10.1210/me.11.6.714 · Cited by 170
Liao, X., Lu, D., Wang, N., Liu, L., Wang, Y., Li, Y., Yan, T., Sun, X., Hu, P., & Zhang, T. (2014) · The FEBS Journal · doi:10.1111/febs.12658 · Cited by 168
Ariyoshi, M., & Schwabe, J. W. R. (2003) · Genes & Development · doi:10.1101/gad.266203 · Cited by 163
Estrogen receptor corepressors -- a role in human breast cancer?
Dobrzycka, K. M., Townson, S. M., Jiang, S., & Oesterreich, S. (2003) · Endocrine Related Cancer · doi:10.1677/erc.0.0100517 · Cited by 160
Receptor-interacting Protein 140 Directly Recruits Histone Deacetylases for Gene Silencing
Wei, L.-N., Hu, X., Chandra, D., Seto, E., & Farooqui, M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m004821200 · Cited by 150
Kim, K., Thu, N., Saville, B., & Safe, S. H. (2003) · Molecular Endocrinology · doi:10.1210/me.2002-0406 · Cited by 141
Chung, Y., Sheu, M., Yang, S., Lin, C., & Yen, S. (2002) · International Journal of Cancer · doi:10.1002/ijc.1614 · Cited by 140
Lee, Y. J., Won, A. J., Lee, J., Jung, J. H., Yoon, S., Lee, B. M., & Kim, H. S. (2012) · International Journal of Medical Sciences · doi:10.7150/ijms.5011 · Cited by 123
Klinge, C. M., Silver, B. F., Driscoll, M. D., Sathya, G., Bambara, R. A., & Hilf, R. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.50.31465 · Cited by 119
Castet, A., Herledan, A., Bonnet, S., Jalaguier, S., Vanacker, J.-M., & Cavaillès, V. (2006) · Molecular Endocrinology · doi:10.1210/me.2005-0227 · Cited by 111
Keeton, E. K., & Brown, M. (2005) · Molecular Endocrinology · doi:10.1210/me.2004-0395 · Cited by 104
The MPA mouse breast cancer model: evidence for a role of progesterone receptors in breast cancer
Lanari, C., Lamb, C. A., Fabris, V. T., Helguero, L. A., Soldati, R., Bottino, M. C., Giulianelli, S., Cerliani, J. P., Wargon, V., & Molinolo, A. (2009) · Endocrine Related Cancer · doi:10.1677/erc-08-0244 · Cited by 103
Nakopoulou, L., Lazaris, A. C., Panayotopoulou, E. G., Giannopoulou, I., Givalos, N., Markaki, S. P., & Keramopoulos, A. (2004) · Journal of Clinical Pathology · doi:10.1136/jcp.2003.008599 · Cited by 101
Clavel‐Chapelon, F. (2002) · Cancer Causes & Control · doi:10.1023/a:1020684821837 · Cited by 99
Raha, P., Thomas, S., Thurn, K. T., Park, J., & Munster, P. N. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0533-z · Cited by 96
Sefrioui, D., Perdrix, A., Sarafan‐Vasseur, N., Dolfus, C., Dujon, A., Picquenot, J., Delacour, J., Cornic, M., Bohers, É., Leheurteur, M., et al. (2015) · International Journal of Cancer · doi:10.1002/ijc.29612 · Cited by 94
Multiple domains of the Receptor-Interacting Protein 140 contribute to transcription inhibition
Castet‐Nicolas, A. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh524 · Cited by 89
Tremblay, G. B., Tremblay, A., Labrie, F., & Giguère, V. (1998) · PubMed · Cited by 88
SAFB2, a New Scaffold Attachment Factor Homolog and Estrogen Receptor Corepressor
Townson, S. M., Dobrzycka, K. M., Lee, A. V., Air, M., Deng, W., Kang, K., Jiang, S., Kioka, N., Michaelis, K., & Oesterreich, S. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m212988200 · Cited by 88
Epigenetic Mechanisms of Tamoxifen Resistance in Luminal Breast Cancer
Abdel-Hafiz, H. A. (2017) · Diseases · doi:10.3390/diseases5030016 · Cited by 87
Légaré, S., Cavallone, L., Mamo, A., Chabot, C., Sirois, I., Magliocco, A. M., Klimowicz, A. C., Tonin, P. N., Buchanan, M., Keilty, D., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3475 · Cited by 83
Self-citationTargeting BIG3–PHB2 interaction to overcome tamoxifen resistance in breast cancer cells
Yoshimaru, T., Komatsu, M., Matsuo, T., Chen, Y., Murakami, Y., Mizuguchi, K., Mizohata, E., Tsuyoshi Inoue, A., Akiyama, M. O., Yamaguchi, R., et al. (2013) · Nature Communications · doi:10.1038/ncomms3443 · Cited by 78
Progesterone facilitates chromosome instability (aneuploidy) in p53 null
Goepfert, T. M., McCarthy, M., Kittrell, F. S., Stephens, C. L., Ullrich, R. L., Brinkley, B. R., & Medina, D. (2000) · The FASEB Journal · doi:10.1096/fj.00-0165com · Cited by 78
Feng, Q. F., & O’Malley, B. W. (2014) · Steroids · doi:10.1016/j.steroids.2014.06.008 · Cited by 72
Scholz, A., Truss, M., & Beato, M. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.8.4360 · Cited by 69
Choi, H., Cho, K. B., Phương, N. T. T., Han, C. Y., Han, H., Hiền, T. T., Choi, H. S., & Kang, K. W. (2013) · Molecular Pharmaceutics · doi:10.1021/mp400287p · Cited by 66
Heldring, N., Nilsson, M., Buehrer, B. M., Treuter, E., & Gustafsson, J.-Α. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.8.3445-3459.2004 · Cited by 65
Role of estrogen receptor α transcriptional coregulators in tamoxifen resistance in breast cancer
Girault, I., Bièche, I., & Lidereau, R. (2006) · Maturitas · doi:10.1016/j.maturitas.2006.06.003 · Cited by 60
Negative regulation of hormone signaling by RIP140
Augereau, P., Badia, É., Balaguer, P., Carascossa, S., Castet‐Nicolas, A., Jalaguier, S., & Cavaillès, V. (2006) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2006.09.005 · Cited by 60
Jiang, S., Meyer, R., Kang, K., Osborne, C. K., Wong, J., & Oesterreich, S. (2005) · Molecular Endocrinology · doi:10.1210/me.2005-0100 · Cited by 59
Co-targeting estrogen receptor and HER2 pathways in breast cancer
Mehta, A., & Tripathy, D. (2013) · The Breast · doi:10.1016/j.breast.2013.09.006 · Cited by 59
Gougèlet, A., Mueller, S. O., Korach, K. S., & Renoir, J. (2007) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2007.03.002 · Cited by 58
Jones, J. L., Daley, B. J., Enderson, B. L., Zhou, J.-R., & Karlstad, M. D. (2002) · The American Surgeon · doi:10.1177/000313480206800612 · Cited by 58
Scaffold Attachment Factor B1 Functions in Development, Growth, and Reproduction
Ivanova, M. M., Dobrzycka, K. M., Jiang, S., Michaelis, K., Meyer, R., Kang, K., Adkins, B. D., Barski, O. A., Zubairy, S., Divisová, J., et al. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.8.2995-3006.2005 · Cited by 56
Chan, C. M. W., Lykkesfeldt, A. E., Parker, M. G., & Dowsett, M. (1999) · PubMed · Cited by 56
Thoughts on tamoxifen resistant breast cancer. Are coregulators the answer or just a red herring?
Graham, J. D., Bain, D. L., Richer, J. K., Jackson, T. A., Tung, L. W., & Horwitz, K. B. (2000) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(00)00101-1 · Cited by 55
Structure-Function Analysis of the Estrogen Receptor α Corepressor Scaffold Attachment Factor-B1
Townson, S. M., Kang, K., Lee, A. V., & Oesterreich, S. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313726200 · Cited by 54
Oesterreich, S. (2003) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10685 · Cited by 53
Arieti, F., Gabus, C., Tambalo, M., Huet, T., Round, A. R., & Thore, S. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku277 · Cited by 52
Hormone-Induced Chromosomal Instability in p53-Null Mammary Epithelium
Pati, D., Haddad, B. R., Haegele, A. D., Thompson, H. J., Kittrell, F. S., Shepard, A., Montagna, C., Zhang, N., Ge, G., Otta, S. K., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-0629 · Cited by 45
SAFB1 Mediates Repression of Immune Regulators and Apoptotic Genes in Breast Cancer Cells
Hammerich‐Hille, S., Kaipparettu, B. A., Tsimelzon, A. I., Creighton, C. J., Jiang, S., Polo, J. M., Melnick, A. M., Meyer, R., & Oesterreich, S. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.066431 · Cited by 44
Smirnov, D. A., Hou, S., & Ricciardi, R. P. (2000) · Virology · doi:10.1006/viro.1999.0181 · Cited by 43
Park, J., Ahn, M. Y., Kim, T. H., Yoon, S., Kang, K. W., Lee, J., Moon, H. R., Jung, J. H., Chung, H. Y., & Kim, H. S. (2011) · Investigational New Drugs · doi:10.1007/s10637-011-9752-z · Cited by 42
Complex Formation and Function of Estrogen Receptor α in Transcription Requires RIP140
Rosell, M., Nevedomskaya, E., Stelloo, S., Nautiyal, J., Poliandri, A., Steel, J. H., Wessels, L. F. A., Carroll, J. S., Parker, M. G., & Zwart, W. T. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3429 · Cited by 41
Riggs, K. A., Wickramasinghe, N., Cochrum, R. K., Watts, M. B., & Klinge, C. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3937 · Cited by 40
Low SAFB levels are associated with worse outcome in breast cancer patients
Hammerich‐Hille, S., Bardout, V. J., Hilsenbeck, S. G., Osborne, C. K., & Oesterreich, S. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0297-6 · Cited by 40
Menopausal hormone therapy and cancer: Changing clinical observations of target site specificity
Chlebowski, R. T., & Anderson, G. L. (2014) · Steroids · doi:10.1016/j.steroids.2014.06.001 · Cited by 39
Chooniedass, S., Vincett, D., Yan, Y., Cooper, C., Hamedani, M. K., Myal, Y., & Leygue, E. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.02.024 · Cited by 34
Estrogen Promotes Breast Cancer Cell Survival in an Inhibitor of Apoptosis (IAP)-dependent Manner
Stanculescu, A., Bembinster, L. A., Borgen, K. R., Bergamaschi, A., Wiley, E. L., & Frasor, J. M. (2010) · Hormones and Cancer · doi:10.1007/s12672-010-0018-6 · Cited by 34
Thomas, S., Thurn, K. T., Raha, P., Chen, S., & Münster, P. N. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068973 · Cited by 32
ICHIKAWA, A., Ando, J., & Suda, K. (2008) · Human Cell · doi:10.1111/j.1749-0774.2008.00048.x · Cited by 31
Estrogen, Selective Estrogen Receptor Modulation, and Coronary Heart Disease: Something or Nothing
Jordan, V. C. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.1.2 · Cited by 31
Kalet, B. T., Anglin, S. R., Handschy, A. V., O’Donoghue, L. E., Halsey, C., Chubb, L. S., Korch, C. T., & Duval, D. L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068815 · Cited by 30
A unifying biology of sex steroid-induced apoptosis in prostate and breast cancers
Maximov, P. Y., Abderrahman, B., Curpan, R. F., Hawsawi, Y. M., Fan, P., & Jordan, V. C. (2017) · Endocrine Related Cancer · doi:10.1530/erc-17-0416 · Cited by 29
Mikami, S., Kanaba, T., Takizawa, N., et al. (2013) · Structure · doi:10.1016/j.str.2013.10.007 · Cited by 27
COUP-TFII inhibits NFkappaB activation in endocrine-resistant breast cancer cells
Litchfield, L. M., Appana, S. N., Datta, S., & Klinge, C. M. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.10.010 · Cited by 24
Maehle, B. O., Collett, K., Tretli, S., Akslen, L. A., & Grotmol, T. (2009) · Apmis · doi:10.1111/j.1600-0463.2009.02510.x · Cited by 24
Varma, H., & Conrad, S. E. (2000) · Oncogene · doi:10.1038/sj.onc.1203827 · Cited by 23
Hashimoto, T., Matsuda, K., & Kawata, M. (2012) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24182 · Cited by 21
Direct Association between the CREB-Binding Protein (CBP) and Nuclear Receptor Corepressor (N-CoR)
Cowger, J. J. M., & Torchia, J. (2006) · Biochemistry · doi:10.1021/bi060562g · Cited by 19
Yoshimaru, T., Komatsu, M., Miyoshi, Y., Honda, J., Sasa, M., & Katagiri, T. (2015) · Cancer Science · doi:10.1111/cas.12654 · Cited by 18
Smith, C. S., Migliaccio, I., Chaubal, V., Wu, M.-F., Pace, M. C., Hartmaier, R. J., Jiang, S., Edwards, D. P., Gutiérrez, M. C., Hilsenbeck, S. G., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2262-7 · Cited by 17
Restall, C. M., Doherty, J. P., Liu, H. B., Genovese, R., Paiman, L., Byron, K. A., Anderson, R. L., & Dear, A. E. (2009) · International Journal of Cancer · doi:10.1002/ijc.24350 · Cited by 17
Wang, T., Liu, J., Zhang, J., Wang, L., Chen, C., & Dai, P. (2015) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2015.03.004 · Cited by 14
Absence of estrogen receptor alpha (ESR1) gene amplification in a series of breast cancers in Taiwan
Chen, J., Hsieh, T.-Y., Chen, H.-Y., Yeh, K., Chen, K.-S., Changchien, Y.-C., Pintye, M., Chang, L., Hwang, C., Chien, H., et al. (2014) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-014-1576-8 · Cited by 14
Tabarestani, S., Ghaderian, S. M. H., Rezvani, H., & Mirfakhraie, R. (2014) · Medical Oncology · doi:10.1007/s12032-014-0896-5 · Cited by 12
Zhang, Z., Yamashita, H., Toyama, T., Yamamoto, Y., Kawasoe, T., Ibusuki, M., Tomita, S., Sugiura, H., Kobayashi, S., Fujii, Y., et al. (2009) · PubMed · Cited by 11
Tumor suppressive actions of the nuclear receptor corepressor 1
Martínez-Iglesias, O. A., Alonso-Merino, E., & Aranda, A. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.04.027 · Cited by 11
Wei, H., Chen, L., Li, J., & Yao, Z. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.04.085 · Cited by 9
Mikami, S., Kanaba, T., Ito, Y., & Mishima, M. (2012) · Biomolecular NMR Assignments · doi:10.1007/s12104-012-9424-8 · Cited by 9
Akt-Induced Tamoxifen Resistance is Associated with Altered FKHR Regulation
Silva-Fisher, J., Cavazos, D., Donzis, E. J., Friedrichs, W. E., Marciniak, R. A., & deGraffenried, L. A. (2007) · Cancer Investigation · doi:10.1080/07357900701513538 · Cited by 9
Cited by
Jiang, Z., Li, W., Hu, X., Zhang, Q., Sun, T., Cui, S., Wang, S., Ouyang, Q., Yin, Y., Geng, C., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30164-0 · Cited by 270
Wang, T. K., Xu, S., Fan, Y., Wu, J., Wang, Z., Chen, Y., & Zhang, Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310476 · Cited by 18
Metadata
- Authors
- Légaré, S., & Basik, M.
- Affiliations
- Jewish General Hospital (CA)
- Corresponding author
- Basik, Mark
- ORCID
- Basik, Mark
- Venue
- Molecular Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2016-07-20
- Volume
- 30
- Issue
- 9
- Pages
- 965-976
- ISSN
- 0888-8809 (ISSN-L)
- 1944-9917
- PMC
- PMC5414611
- OpenAlex
- W2491547442
- Cited by
- 63
- References
- 121
- Citations by year
- 2026: 5 · 2025: 4 · 2024: 5 · 2023: 7 · 2022: 10 · 2021: 8 · 2020: 11 · 2019: 5 · 2018: 3 · 2017: 5
- FWCI
- 0.58
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Molecular Endocrinology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- tamoxifen resistance, breast cancer, estrogen receptor alpha, nuclear receptor corepressor, histone deacetylase, histone deacetylase inhibitors, gene repression, epigenetic regulation, endocrine therapy, drug resistance reversal
- MeSH terms
- Nuclear Receptor Interacting Protein 1, Animals, Breast Neoplasms, Female, Histone Deacetylases, Humans, Nuclear Proteins, Tamoxifen, Matrix Attachment Region Binding Proteins, Adaptor Proteins, Signal Transducing, COUP Transcription Factor II, Nuclear Receptor Co-Repressor 1, Nuclear Receptor Co-Repressor 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.